Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
The Relationship Between Heart Function and Metabolism in HFpEF Patients
HFpEF has gradually become the most common form of heart failure. Studies have found that metabolic abnormalities and chronic inflammation ultimately lead to HFpEF by promoting heart remodeling.
- Trial name
- NCT05053256
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Chongqing Medical University
Heart Failure With Preserved Ejection Fraction
Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction
To assess the impact of PADN combined with guideline-directed medical therapy (GDMT) versus a sham procedure with GDMT on clinical outcomes in heart failure (HF) patients with preserved left ventricular ejection fraction…
- Trial name
- PADN-HFpEF (NCT07331220)
- Testing
- PADN, GDMT
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Heart Failure With Preserved Ejection Fraction (HFPEF)
Role of Cardiopulmonary Exercise Testing in People With Heart Failure With Preserved Ejection Fraction
Heart failure affects 1-2% of the adult population. Up to half of these patients have apparently normal heart pumping function, known as heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT07394010
- Testing
- Cardiopulmonary Exercise Test
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Ulster
Congestive Heart Failure, Tricuspid Regurgitation
Hemodynamic Implications of Transcatheter Tricuspid Valve Repair in HFpEF Patients
The aim of the study is to investigate the pathophysiological implications of transcatheter tricuspid valve edge-to-edge repair in patient with heart failure and preserved ejection fraction and severe tricuspid regurgitation.
- Trial name
- HERACLES-HFpEF (NCT04782908)
- Testing
- Transcatheter tricuspid valve edge-to-edge repair
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heart Center Leipzig - University Hospital
Heart Failure With Preserved Ejection Fraction (HFPEF)
Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.
More than half of heart failure patients have preserved ejection fraction (HFpEF), a condition caused by increased wall stiffness that impairs proper heart filling.
- Trial name
- NCT06731738
- Testing
- Gadoteric acid, Mangafodipir trisodium injection
- Where
- Norway
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- IC TARGETS AS
Type 2 Diabetes, Heart Failure
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07390110
- Testing
- Oral semaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 25,664 people
- Sponsor
- Brigham and Women's Hospital
HFpEF - Heart Failure With Preserved Ejection Fraction, Colchicine
Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
Heart failure with preserved left ventricular ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates.
- Trial name
- NCT05637398
- Testing
- Colchicine
- Where
- 2 sites in Russia
- Volunteers
- 42 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Heart Failure With Preserved Ejection Fraction
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF…
- Trial name
- PARALLAX (NCT03066804)
- Testing
- sacubitril/valsartan, Enalapril, Valsartan
- Where
- 380 sites in United States, Argentina and 30 more
- Volunteers
- 2,572 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure With Preserved Ejection Fraction
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Acute heart failure (AHF) is defined as rapid onset or rapid worsening of typical signs and symptoms of heart failure (HF) according to the 2016 European Society of Cardiology Guidelines.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- FUTURE-HIT (NCT05204238)
- Testing
- Transthoracic Echocardiography
- Where
- 31 sites in Australia, Belgium and 10 more
- Volunteers
- 998 people
- Sponsor
- University of Siena
Heart Failure
Cohort Study of Heart Failure With Preserved Ejection Fraction in Chinese Han
To analyze factors contributing to the development and prognosis of heart failure with preserved ejection fraction.
- Trial name
- NCT05278026
- Testing
- guideline recommended routine treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Home-Based Cardiac Rehabilitation for Patients With Heart Failure
The vast majority of individuals with heart failure do not participate in center based cardiac rehabilitation (CBCR). While steps to increase utilization of CBCR are important, many individuals will still not participate for a…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases
- Trial name
- MOBILE HEART (NCT06479876)
- Testing
- HBCR
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University Medical Center
Heart Failure, Diastolic
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT03133793
- Testing
- CoQ10, D-Ribose Oral Powder
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Heart Failure, Sarcopenia
The Sarcopenia Study
The goal of this cross-sectional study is to investigate the prevalence of sarcopenia in patients with Heart Failure. The main question it aims to answer is: Whether there is a difference in the prevalence of sarcopenia across…
- Conditions
- Heart Failure, Sarcopenia, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT05888688
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Microvascular Coronary Artery Disease, Heart Failure With Reduced Ejection Fraction
CMR Assessment of Cardiac Microvascular Dysfunction in Patients With HFpEF
Heart failure with preserved ejection fraction (HFpEF) causes hospitalizations, premature mortality and high health care costs. This is also due to poor understanding of HFpEF pathogenesis and, thus, lack of specific therapies.
- Trial name
- MAPPED (NCT06316661)
- Testing
- stress perfusion cardiac magnetic resonance, cardiopulmonary exercise test
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Heart Failure With Preserved Ejection Fraction
Right Ventricular Function and Pulmonary Hypertension in HFpEF
In patients with heart failure and preserved ejection fraction (HFpEF) right ventricular (RV) systolic and diastolic dysfunction are prognostically and functionally relevant factors but have mechanistically been neglected so far.
- Trial name
- HFpEF-PHT (NCT05055180)
- Testing
- Invasive hemodynamics and myocardial biopsies
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Heart Center Leipzig - University Hospital
Heart Failure With Preserved Ejection Fraction, Obesity
Adipose Tissue Inflammation in HFpEF
To evaluate the role of adipose tissue inflammation in patients with heart failure with preserved ejection fraction (HFpEF). Patients undergoing coronary artery bypass grafting with HFpEF and without heart failure will be…
- Trial name
- SLIM-HFpEF (NCT04886713)
- Testing
- Adipose and myocardial tissue sampling, Cardiac magnetic resonance imaging, Cardiopulmonary exercise testing
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heart Center Leipzig - University Hospital
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
- Conditions
- Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- NCT03624010
- Testing
- Levosimendan
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure With Preserved Ejection Fraction
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition…
- Trial name
- DELIVER (NCT03619213)
- Testing
- Dapagliflozin
- Where
- 348 sites in United States, Argentina and 18 more
- Volunteers
- 6,263 people
- Sponsor
- AstraZeneca
Heart Failure, Diastolic
Respiratory Muscle Function in Heart Failure
This study is being done because investigators are trying to determine how respiratory muscle and lung function influence the exercise responses in heart failure and healthy participants.
- Trial name
- NCT03924479
- Testing
- PowerBreathe (Breathing muscle training)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic